Cargando…

Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide

PURPOSE: Leflunomide (LEF) is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA) and the action of which may be modified by sex hormones. The aim of this study was to examine the association between CAG repeat polymorphism in the androgen receptor (AR) gene and the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziedziejko, Violetta, Kurzawski, Mateusz, Safranow, Krzysztof, Ossowski, Andrzej, Piatek, Jaroslaw, Parafiniuk, Miroslaw, Chlubek, Dariusz, Pawlik, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303044/
https://www.ncbi.nlm.nih.gov/pubmed/21997404
http://dx.doi.org/10.1007/s00228-011-1131-3
_version_ 1782226714387021824
author Dziedziejko, Violetta
Kurzawski, Mateusz
Safranow, Krzysztof
Ossowski, Andrzej
Piatek, Jaroslaw
Parafiniuk, Miroslaw
Chlubek, Dariusz
Pawlik, Andrzej
author_facet Dziedziejko, Violetta
Kurzawski, Mateusz
Safranow, Krzysztof
Ossowski, Andrzej
Piatek, Jaroslaw
Parafiniuk, Miroslaw
Chlubek, Dariusz
Pawlik, Andrzej
author_sort Dziedziejko, Violetta
collection PubMed
description PURPOSE: Leflunomide (LEF) is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA) and the action of which may be modified by sex hormones. The aim of this study was to examine the association between CAG repeat polymorphism in the androgen receptor (AR) gene and the response to treatment with LEF in women with RA. METHODS: We studied 114 women diagnosed with RA and treated with LEF (20 mg daily). Follow-up was 12 months. CAG repeat polymorphism was determined using polymerase chain reaction (PCR) and subsequent fragment analysis by capillary electrophoresis. RESULTS: Analysis revealed no statistically significant associations between CAG repeat polymorphism in the AR gene and improvement of disease activity parameters: erythrocyte sedimentation rate, serum C-reactive protein, patient’s global assessment of disease activity on a visual analog scale (VAS), disease activity score of 28 joints (DAS28), and swollen and tender joint count. CONCLUSION: Our results suggest no correlation between CAG repeat polymorphism in the AR gene and response to treatment with LEF in women with RA.
format Online
Article
Text
id pubmed-3303044
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-33030442012-03-22 Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide Dziedziejko, Violetta Kurzawski, Mateusz Safranow, Krzysztof Ossowski, Andrzej Piatek, Jaroslaw Parafiniuk, Miroslaw Chlubek, Dariusz Pawlik, Andrzej Eur J Clin Pharmacol Pharmacogenetics PURPOSE: Leflunomide (LEF) is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA) and the action of which may be modified by sex hormones. The aim of this study was to examine the association between CAG repeat polymorphism in the androgen receptor (AR) gene and the response to treatment with LEF in women with RA. METHODS: We studied 114 women diagnosed with RA and treated with LEF (20 mg daily). Follow-up was 12 months. CAG repeat polymorphism was determined using polymerase chain reaction (PCR) and subsequent fragment analysis by capillary electrophoresis. RESULTS: Analysis revealed no statistically significant associations between CAG repeat polymorphism in the AR gene and improvement of disease activity parameters: erythrocyte sedimentation rate, serum C-reactive protein, patient’s global assessment of disease activity on a visual analog scale (VAS), disease activity score of 28 joints (DAS28), and swollen and tender joint count. CONCLUSION: Our results suggest no correlation between CAG repeat polymorphism in the AR gene and response to treatment with LEF in women with RA. Springer-Verlag 2011-10-14 2012 /pmc/articles/PMC3303044/ /pubmed/21997404 http://dx.doi.org/10.1007/s00228-011-1131-3 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Pharmacogenetics
Dziedziejko, Violetta
Kurzawski, Mateusz
Safranow, Krzysztof
Ossowski, Andrzej
Piatek, Jaroslaw
Parafiniuk, Miroslaw
Chlubek, Dariusz
Pawlik, Andrzej
Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
title Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
title_full Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
title_fullStr Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
title_full_unstemmed Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
title_short Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
title_sort lack of association between cag repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
topic Pharmacogenetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303044/
https://www.ncbi.nlm.nih.gov/pubmed/21997404
http://dx.doi.org/10.1007/s00228-011-1131-3
work_keys_str_mv AT dziedziejkovioletta lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide
AT kurzawskimateusz lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide
AT safranowkrzysztof lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide
AT ossowskiandrzej lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide
AT piatekjaroslaw lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide
AT parafiniukmiroslaw lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide
AT chlubekdariusz lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide
AT pawlikandrzej lackofassociationbetweencagrepeatpolymorphismintheandrogenreceptorgeneandtheoutcomeofrheumatoidarthritistreatmentwithleflunomide